BMY
Bristol-Myers Squibb Company
$58.03
-$1.43(-2.40%)
63
Overall
85
Value
54
Tech
52
Quality
Market Cap
$119.07B
Volume
8.16M
52W Range
$42.52 - $62.89
Target Price
$62.77
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $38.9B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B | ||
| Total Revenue | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $4.9B | $6.1B | $6.5B | $8.1B | $11.8B | $9.9B | $10.1B | $10.7B | $14.0B | $13.9B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $14.5B | $14.7B | $16.1B | $18.1B | $30.7B | $36.4B | $36.0B | $34.3B | $34.3B | $34.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $9.9B | $11.2B | $10.9B | $15.5B | $18.8B | $17.9B | $26.9B | $17.1B | $19.6B | $17.2B | ||
| Research & Development | $4.9B | $6.5B | $6.3B | $6.1B | $11.1B | $10.2B | $9.5B | $9.3B | $11.2B | $10.0B | ||
| Research Expense | $4.9B | $6.5B | $6.3B | $6.1B | $11.1B | $10.2B | $9.5B | $9.3B | $11.2B | $10.0B | ||
| Selling, General & Administrative | $4.9B | $4.8B | $4.6B | $4.9B | $7.7B | $7.7B | $7.8B | $7.8B | $8.4B | $7.3B | ||
| Selling & Marketing Expenses | $789.0M | $740.0M | $672.0M | $633.0M | $990.0M | $1.3B | $1.3B | $1.4B | $1.5B | -- | ||
| General & Administrative Expenses | $4.9B | $4.8B | $4.6B | $4.9B | $7.7B | $7.7B | $7.8B | $7.8B | $8.4B | $7.3B | ||
| Salaries & Wages | $-69.0M | $-59.0M | $-41.0M | $-87.0M | $-158.0M | $-120.0M | $-91.0M | -- | -- | -- | ||
| Depreciation & Amortization | $448.0M | $682.0M | $505.0M | $554.0M | $586.0M | $559.0M | $587.0M | $611.0M | $651.0M | -- | ||
| Depreciation & Amortization | $448.0M | $682.0M | $505.0M | $554.0M | $586.0M | $559.0M | $587.0M | -- | -- | -- | ||
| Amortization | $6.9B | $6.9B | $6.5B | $64.0B | $53.3B | $42.5B | $35.9B | $27.1B | $23.3B | -- | ||
| Other Operating Expenses | $-49.0M | $-173.0M | $-48.0M | $-170.0M | $-76.0M | $-66.0M | $-53.0M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $24.1B | $3.4B | $5.3B | $21.8B | $33.1B | $29.7B | $18.7B | $17.2B | $14.8B | $17.0B | ||
| EBITDA | $6.4B | $6.1B | $6.8B | $8.7B | $4.9B | $20.1B | $19.2B | $19.4B | $3.2B | $15.2B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $167.0M | $196.0M | $183.0M | $656.0M | $1.4B | $1.3B | $1.2B | $1.2B | $1.9B | $1.9B | ||
| Intinc | $105.0M | $126.0M | $173.0M | $464.0M | $121.0M | $39.0M | $171.0M | $449.0M | $478.0M | $586.0M | ||
| Net Non-Operating Interest Income/Expense | $-62.0M | $-70.0M | $-10.0M | $-192.0M | $-1.3B | $-1.3B | $1.2B | $449.0M | $-1.5B | $-1.3B | ||
| Gain on Sale of Securities | $-45.0M | $23.0M | $7.0M | $275.0M | $1.2B | $745.0M | $17.0M | $-160.0M | $16.0M | $280.0M | ||
| Other Income/Expense | $-1.3B | $-1.7B | $-854.0M | $938.0M | $-2.3B | $-720.0M | $-159.0M | $-1.2B | $893.0M | $674.0M | ||
| Other Special Charges | $1.3B | $1.7B | $854.0M | $-938.0M | $2.3B | $720.0M | $-576.0M | $1.2B | $-893.0M | $-674.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $213.0M | $-319.0M | $4.1B | $-3.4B | $-10.0M | $-19.0M | $-7.0M | $365.0M | $635.0M | $563.0M | ||
| Special Income Charges | $-275.0M | $806.0M | $-4.2B | $3.3B | $183.0M | $-63.0M | $-171.0M | $-387.0M | $-719.0M | $-997.0M | ||
| Impairment of Capital Assets | $15.0M | $241.0M | $64.0M | $15.0M | $21.0M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $5.9B | $5.1B | $5.9B | $5.2B | $-5.5B | $9.4B | $8.9B | $9.6B | $-6.4B | $11.2B | ||
| Pre-Tax Income | $5.9B | $5.1B | $6.0B | $5.0B | $-6.9B | $8.1B | $7.7B | $8.4B | $-8.4B | $9.3B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $1.4B | $4.2B | $1.0B | $1.5B | $2.1B | $1.1B | $1.4B | $400.0M | $554.0M | $2.3B | ||
| NET INCOME | ||||||||||||
| Net Income | $4.5B | $1.0B | $4.9B | $3.4B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | $7.1B | ||
| Net Income (Continuing Operations) | $4.5B | $1.0B | $4.9B | $3.4B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | $7.1B | ||
| Net Income (Discontinued Operations) | $4.5B | $1.0B | $4.9B | $3.4B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | $7.1B | ||
| Net Income (Common Stockholders) | $23.9B | $1.0B | $10.1B | $19.3B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | $7.1B | ||
| Normalized Income | $4.2B | $2.6B | $-27.2B | $-38.5B | $-6.3B | -- | -- | -- | -- | $10.6B | ||
| TOTALS | ||||||||||||
| Total Expenses | $14.8B | $17.3B | $17.4B | $23.6B | $30.6B | $27.8B | $37.1B | $27.8B | $33.5B | $31.2B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.7B | $1.6B | $1.6B | $1.7B | $2.3B | $2.2B | $2.1B | $2.1B | $2.0B | $2.0B | ||
| Average Shares Outstanding (Diluted) | $1.7B | $1.7B | $1.6B | $1.7B | $2.3B | $2.2B | $2.1B | $2.1B | $2.0B | $2.0B | ||
| Shares Outstanding | $1.7B | $1.6B | $1.6B | $2.3B | $2.2B | $2.2B | $2.1B | $2.0B | $2.0B | $2.0B | ||
| Basic EPS | $2.67 | $0.61 | $3.01 | $2.02 | $-3.99 | $3.15 | $2.97 | $3.88 | $-4.41 | $3.47 | ||
| Basic EPS (Continuing Operations) | $2.67 | $0.61 | $3.01 | $2.02 | $-3.99 | $3.15 | $2.97 | $3.88 | $-4.41 | $3.47 | ||
| Diluted EPS | $2.65 | $0.61 | $3.01 | $2.01 | $-3.99 | $3.12 | $2.95 | $3.86 | $-4.41 | $3.46 | ||
| Diluted EPS (Continuing Operations) | $2.65 | $0.61 | $3.01 | $2.01 | $-3.99 | $3.12 | $2.95 | $3.86 | $-4.41 | $3.46 | ||
| Dividend Per Share | $1.53 | $1.57 | $1.61 | $1.68 | $1.84 | $2.01 | $2.19 | $2.31 | $2.42 | $2.49 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | -- | -- | -- | $657.0M | -- | -- | -- | -- | -- | -- | ||
| Commission Expenses | -- | -- | -- | -- | $24.4B | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | $77.0M | $75.0M | $93.0M | $-4.0M | $72.0M | $231.0M | $-108.0M | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $77.0M | $75.0M | $93.0M | $-4.0M | $72.0M | $231.0M | $-108.0M | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | $564.0M | $164.0M | $178.0M | $1.2B | $55.0M | $9.0M | $211.0M | -- | $-15.0M | -- | ||
| Interest Expense Operating | $-191.0M | $-215.0M | $-218.0M | $-414.0M | $-1.6B | $-1.5B | $-1.4B | -- | -- | -- | ||
| Marketing Expense | $789.0M | $740.0M | $672.0M | $633.0M | $990.0M | $1.3B | $1.3B | -- | -- | -- | ||
| Minority Interests | $-50.0M | $32.0M | $-27.0M | $-21.0M | $-20.0M | $-20.0M | $-18.0M | $-15.0M | $-15.0M | -- | ||
| Net Income Discontinuous Operations | $564.0M | $164.0M | $178.0M | $1.2B | $55.0M | $9.0M | $211.0M | -- | $-15.0M | -- | ||
| Net Income Extraordinary | -- | -- | $4.9B | $3.5B | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $47.0M | $-487.0M | $76.0M | $77.0M | $-194.0M | $82.0M | $178.0M | $-390.0M | $84.0M | $434.0M | ||
| Other Gand A | $4.9B | $4.8B | $4.6B | $4.9B | $7.7B | $7.7B | $7.8B | $7.8B | $8.4B | $7.3B | ||
| Other Impairment Of Capital Assets | $33.0M | $80.0M | $84.0M | $-27.0M | $1.1B | $1.2B | $101.0M | -- | -- | -- | ||
| Other Taxes | -- | -- | -- | $4.5B | -- | -- | -- | -- | -- | -- | ||
| Other Write Off | -- | $-3.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $145.0M | $120.0M | $130.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $213.0M | $-319.0M | $4.1B | $-3.4B | $-10.0M | $-19.0M | $-7.0M | $365.0M | $635.0M | $563.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BMY | $58.03 | -2.4% | 8.16M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bristol-Myers Squibb Company Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW